Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Sorafenib, a tyrosine kinase inhibitor, is a key chemotherapy drug.
• Challenges with sorafenib include poor water solubility, toxicity, and side effects.
• Nanocarriers offer a promising strategy to improve drug delivery and efficacy.

Purpose of the Study:

• To develop novel sorafenib-based nanoparticles using hybrid nucleoside-lipids.
• To evaluate the physicochemical properties and anticancer activity of these nanoparticles.
• To assess the potential of these nanocarriers as an improved drug delivery system.

Main Methods:

• Synthesis and characterization of sorafenib-loaded solid lipid nanoparticles (SLNs) stabilized by nucleoside-lipids.
• Zeta potential measurements to determine surface charge.
• Transmission electron microscopy (TEM) for nanoparticle morphology and size analysis.
• In vitro biological studies on cancer cell lines to assess anticancer activity.

Main Results:

• Nucleoside-lipid-stabilized SLNs were successfully prepared, with sizes around 200 nm.
• Nanoparticles exhibited tunable zeta potential (negative or positive) based on nucleoside-lipid charge.
• Sorafenib-loaded SLNs demonstrated enhanced anticancer activity compared to free sorafenib across tested cancer cell lines.
• High concentrations of sorafenib-loaded SLNs induced complete cancer cell death.

Conclusions:

• Nucleoside-lipid-based SLNs represent a viable drug delivery system for sorafenib.
• These nanoparticles effectively improve the anticancer efficacy of sorafenib.
• This approach holds potential for overcoming limitations of conventional sorafenib chemotherapy.